Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis

Kwang Hyub Han, Jinsil Seong, Ja Kyung Kim, Sang Hoon Ahn, Do Yun Lee, Chae Yoon Chon

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

BACKGROUND. Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have a particularly grave prognosis. In the current study, an attempt was made to localize chemoradiation therapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC with PVT and good reserve liver function. The objective of the current study was to evaluate the therapeutic effect of localized CCRT followed by HAIC as a new treatment modality for these patients. METHODS. Between January 1998 and December 2003, 40 patients were recruited. Concurrent regional chemotherapy using an intra-arterial implanted port plus localized external beam radiotherapy was performed with a total of 45 gray (Gy) over 5 weeks with conventional fractionation and hepatic arterial infusion of 5-fluorouracil (5-FU), which was administered during the first and fifth weeks of radiotherapy. One month after localized CCRT, HAIC with 5-FU and cisplatin was administered every 4 weeks. RESULTS. One month after localized CCRT, an objective response was observed on the intention-to-treat analysis in 18 of 40 patients (45%). The actuarial 3-year overall survival rate was 24.1% and the median survival time was 13.1 months from the start of radiation treatment. Responders after localized CCRT demonstrated significantly better survival (P 5.033) than nonresponders. CONCLUSIONS. The substantial response rate as well as median survival time noted in the current study encourages the use of this new approach in patients with locally advanced HCC with PVT.

Original languageEnglish
Pages (from-to)995-1003
Number of pages9
JournalCancer
Volume113
Issue number5
DOIs
Publication statusPublished - 2008 Sep 1

Fingerprint

Portal Vein
Hepatocellular Carcinoma
Thrombosis
Clinical Trials
Liver
Drug Therapy
Fluorouracil
Survival
Radiotherapy
Therapeutics
Intention to Treat Analysis
Therapeutic Uses
Cisplatin
Survival Rate
Radiation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{931a9fd1c4994ec78d9f349e879cc9a5,
title = "Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis",
abstract = "BACKGROUND. Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have a particularly grave prognosis. In the current study, an attempt was made to localize chemoradiation therapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC with PVT and good reserve liver function. The objective of the current study was to evaluate the therapeutic effect of localized CCRT followed by HAIC as a new treatment modality for these patients. METHODS. Between January 1998 and December 2003, 40 patients were recruited. Concurrent regional chemotherapy using an intra-arterial implanted port plus localized external beam radiotherapy was performed with a total of 45 gray (Gy) over 5 weeks with conventional fractionation and hepatic arterial infusion of 5-fluorouracil (5-FU), which was administered during the first and fifth weeks of radiotherapy. One month after localized CCRT, HAIC with 5-FU and cisplatin was administered every 4 weeks. RESULTS. One month after localized CCRT, an objective response was observed on the intention-to-treat analysis in 18 of 40 patients (45{\%}). The actuarial 3-year overall survival rate was 24.1{\%} and the median survival time was 13.1 months from the start of radiation treatment. Responders after localized CCRT demonstrated significantly better survival (P 5.033) than nonresponders. CONCLUSIONS. The substantial response rate as well as median survival time noted in the current study encourages the use of this new approach in patients with locally advanced HCC with PVT.",
author = "Han, {Kwang Hyub} and Jinsil Seong and Kim, {Ja Kyung} and Ahn, {Sang Hoon} and Lee, {Do Yun} and Chon, {Chae Yoon}",
year = "2008",
month = "9",
day = "1",
doi = "10.1002/cncr.23684",
language = "English",
volume = "113",
pages = "995--1003",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. / Han, Kwang Hyub; Seong, Jinsil; Kim, Ja Kyung; Ahn, Sang Hoon; Lee, Do Yun; Chon, Chae Yoon.

In: Cancer, Vol. 113, No. 5, 01.09.2008, p. 995-1003.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis

AU - Han, Kwang Hyub

AU - Seong, Jinsil

AU - Kim, Ja Kyung

AU - Ahn, Sang Hoon

AU - Lee, Do Yun

AU - Chon, Chae Yoon

PY - 2008/9/1

Y1 - 2008/9/1

N2 - BACKGROUND. Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have a particularly grave prognosis. In the current study, an attempt was made to localize chemoradiation therapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC with PVT and good reserve liver function. The objective of the current study was to evaluate the therapeutic effect of localized CCRT followed by HAIC as a new treatment modality for these patients. METHODS. Between January 1998 and December 2003, 40 patients were recruited. Concurrent regional chemotherapy using an intra-arterial implanted port plus localized external beam radiotherapy was performed with a total of 45 gray (Gy) over 5 weeks with conventional fractionation and hepatic arterial infusion of 5-fluorouracil (5-FU), which was administered during the first and fifth weeks of radiotherapy. One month after localized CCRT, HAIC with 5-FU and cisplatin was administered every 4 weeks. RESULTS. One month after localized CCRT, an objective response was observed on the intention-to-treat analysis in 18 of 40 patients (45%). The actuarial 3-year overall survival rate was 24.1% and the median survival time was 13.1 months from the start of radiation treatment. Responders after localized CCRT demonstrated significantly better survival (P 5.033) than nonresponders. CONCLUSIONS. The substantial response rate as well as median survival time noted in the current study encourages the use of this new approach in patients with locally advanced HCC with PVT.

AB - BACKGROUND. Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have a particularly grave prognosis. In the current study, an attempt was made to localize chemoradiation therapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in patients with locally advanced HCC with PVT and good reserve liver function. The objective of the current study was to evaluate the therapeutic effect of localized CCRT followed by HAIC as a new treatment modality for these patients. METHODS. Between January 1998 and December 2003, 40 patients were recruited. Concurrent regional chemotherapy using an intra-arterial implanted port plus localized external beam radiotherapy was performed with a total of 45 gray (Gy) over 5 weeks with conventional fractionation and hepatic arterial infusion of 5-fluorouracil (5-FU), which was administered during the first and fifth weeks of radiotherapy. One month after localized CCRT, HAIC with 5-FU and cisplatin was administered every 4 weeks. RESULTS. One month after localized CCRT, an objective response was observed on the intention-to-treat analysis in 18 of 40 patients (45%). The actuarial 3-year overall survival rate was 24.1% and the median survival time was 13.1 months from the start of radiation treatment. Responders after localized CCRT demonstrated significantly better survival (P 5.033) than nonresponders. CONCLUSIONS. The substantial response rate as well as median survival time noted in the current study encourages the use of this new approach in patients with locally advanced HCC with PVT.

UR - http://www.scopus.com/inward/record.url?scp=52049096005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049096005&partnerID=8YFLogxK

U2 - 10.1002/cncr.23684

DO - 10.1002/cncr.23684

M3 - Article

C2 - 18615601

AN - SCOPUS:52049096005

VL - 113

SP - 995

EP - 1003

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -